How Much Does Evenity (Romosozumab) Cost in Massachusetts in 2026?

Massachusetts Retail Pricing for Evenity in 2026

The average cash-pay price for Evenity across Massachusetts retail pharmacies sits at $1,825 per month in 2026, matching Amgen's wholesale acquisition cost. Because romosozumab is a biologic administered as two prefilled syringes per dose (each containing 105 mg for a combined 210 mg), pricing is standardized with little variation between pharmacy chains.

A complete 12-month treatment course runs approximately $21,900 before insurance. Specialty pharmacies such as CVS Specialty, Accredo, and OptumRx handle most Evenity dispensing in Massachusetts, since the drug requires cold-chain shipping and falls under specialty tier formulary placement. Some patients receive their injections at infusion centers or physician offices, which may bill under medical benefit (Part B-style) rather than pharmacy benefit, altering cost-sharing calculations.

Compared to other osteoporosis biologics, Evenity's monthly cost exceeds denosumab (Prolia) at roughly $1,150 per six-month injection but covers a shorter total treatment window. The ARCH trial (N=4,093) demonstrated that romosozumab reduced new vertebral fractures by 48% compared to alendronate at 24 months, which helps justify the premium pricing to payers when prior authorization submissions reference fracture risk reduction data [1].

Massachusetts does not cap specialty drug copays through state law the way some states do, so commercial plan members may face coinsurance of 20-40% on specialty-tier drugs without manufacturer assistance.

Massachusetts Medicaid Coverage for Romosozumab

MassHealth (Massachusetts Medicaid) covers Evenity with prior authorization for severe osteoporosis. The PA process typically requires documentation of a T-score of -2.5 or lower on DXA scan, history of fragility fracture, or failure of at least one prior antiresorptive agent such as alendronate or denosumab.

Approval timelines vary. Standard PA decisions from MassHealth take up to 14 business days, while urgent requests can receive determination within 24-72 hours. Prescribers should submit the PA with DXA results, fracture history, and documentation of prior therapy trials. The Endocrine Society's 2020 clinical practice guideline recommends romosozumab as a first-line option for patients at very high fracture risk, defined as a recent fracture within the past 2 years, T-score below -3.0, or high FRAX probability [2]. Referencing this guideline in PA submissions strengthens the clinical rationale.

MassHealth members pay $0 out of pocket once the PA is approved. The drug is typically dispensed through a MassHealth-contracted specialty pharmacy. Denials can be appealed through MassHealth's fair hearing process, and providers report that including FRAX 10-year fracture probability scores above 20% for major osteoporotic fracture improves overturn rates on appeal.

"For patients over 65 dually enrolled in Medicare and MassHealth, coverage typically routes through Medicare Part B when administered in a clinical setting, with MassHealth picking up remaining cost-sharing," notes the MassHealth pharmacy benefit guidance. This dual-eligible pathway eliminates most out-of-pocket expense.

Insurance Coverage Across Massachusetts Plans

Most major commercial insurers in Massachusetts cover Evenity on specialty tier with prior authorization. Coverage specifics vary by plan.

Blue Cross Blue Shield of Massachusetts places Evenity on its specialty formulary tier and requires PA demonstrating high fracture risk plus inadequate response to or intolerance of oral bisphosphonates. Harvard Pilgrim Health Care follows a similar PA protocol. Tufts Health Plan covers romosozumab under specialty pharmacy benefit with step therapy requirements, generally expecting a trial of alendronate or risedronate before approval.

Medicare Part D plans in Massachusetts typically classify Evenity as a specialty-tier drug with 25-33% coinsurance during the initial coverage phase. Once a patient reaches the catastrophic coverage threshold ($8,000 in true out-of-pocket costs for 2026), coinsurance drops to 5%. For patients receiving injections in a physician's office, Medicare Part B may cover Evenity under the medical benefit with standard 20% coinsurance after the Part B deductible.

The FDA-approved prescribing information for Evenity includes a boxed warning about increased risk of myocardial infarction, stroke, and cardiovascular death [3]. Insurers use this warning to restrict coverage to patients without a cardiovascular event within the prior 12 months. PA submissions should explicitly document cardiovascular history clearance.

According to the FRAME trial (N=7,180), romosozumab reduced new vertebral fractures by 73% versus placebo at 12 months, with a number needed to treat (NNT) of 59 for clinical fractures [4]. Payers increasingly recognize these fracture reduction data when evaluating coverage.

The Amgen / UCB Copay Savings Card

Amgen offers the Evenity Complete copay card for commercially insured patients, potentially reducing monthly out-of-pocket costs to $0. The card covers up to $15,000 per year in copay or coinsurance assistance. Patients must have commercial insurance that covers Evenity and cannot use the card alongside Medicare, Medicaid, or other government-funded programs.

Enrollment is available through Evenity Complete (Amgen's patient support hub) or through the prescribing physician's office. Processing typically takes 3-5 business days after enrollment. The savings card applies at the specialty pharmacy point of sale, so patients should confirm their dispensing pharmacy accepts the card before the first fill.

For patients whose commercial insurance denies coverage entirely, the Evenity Complete program also provides free drug through Amgen's patient assistance program for those meeting income eligibility requirements (generally household income at or below 300% of the federal poverty level). In 2026, that threshold equals approximately $47,790 for a single-person household.

Massachusetts residents may also access assistance through the Health Safety Net program for uninsured or underinsured individuals, though biologic coverage through this program is limited and case-by-case.

Compounded Romosozumab in Massachusetts

Compounded romosozumab is available in Massachusetts through licensed 503A compounding pharmacies. Under federal law, Section 503A of the Food, Drug, and Cosmetic Act permits pharmacies to compound drugs based on individual prescriptions when a prescriber-patient relationship exists.

However, compounded biologics carry significant differences from FDA-approved products. The FDA's guidance on compounding distinguishes between small-molecule compounding and biologic compounding, with biologics facing additional scrutiny under the BPCIA framework [5]. Romosozumab is a humanized monoclonal antibody produced through recombinant DNA technology. True compounding of a monoclonal antibody from raw materials is not standard 503A practice. What 503A pharmacies may offer is repackaging or dose-preparation services rather than de novo synthesis.

Patients considering compounded options should verify that the pharmacy holds a valid Massachusetts Board of Registration in Pharmacy compounding license. The Massachusetts Board conducts inspections of 503A facilities. Pricing for compounded preparations, where genuinely available, varies widely, and patients should confirm the specific formulation matches the FDA-approved 210 mg dose.

The cost advantage of compounded products can be substantial in many drug categories. For romosozumab specifically, patients should discuss with their prescriber whether any compounded alternative provides equivalent sclerostin-inhibitor activity and bioavailability, as these factors directly affect fracture risk reduction outcomes demonstrated in clinical trials.

Telehealth Prescribing of Evenity in Massachusetts

Massachusetts permits telehealth prescribing of Evenity. The state's telehealth parity law (M.G.L. c. 175, § 47BB) requires insurers to cover telehealth visits at the same rate as in-person visits, which extends to specialty consultations for osteoporosis management and romosozumab prescribing.

An endocrinologist or rheumatologist can evaluate DXA scan results, review fracture history, assess cardiovascular risk, and initiate a romosozumab prescription through a video visit. The prescription is then sent to a specialty pharmacy for dispensing. Patients self-administer the two subcutaneous injections monthly, or arrange for administration at a local clinic or home health visit.

Telehealth access is particularly relevant for Massachusetts residents in western counties (Berkshire, Franklin, Hampshire) where endocrinology specialists are less concentrated. The USPSTF recommends osteoporosis screening for all women aged 65 and older and for younger postmenopausal women with elevated fracture risk [6]. Telehealth expands access to the specialist evaluation needed to initiate romosozumab after screening identifies high-risk patients.

Initial telehealth consultations for Evenity should include review of recent DXA results (within 24 months), basic metabolic panel including calcium and vitamin D levels, and cardiovascular risk assessment. Follow-up visits at 6 and 12 months monitor treatment response and plan transition to an antiresorptive agent after the 12-dose romosozumab course.

Transition Planning After the 12-Month Course

Romosozumab is FDA-approved for a maximum of 12 monthly doses. The bone-forming effect of sclerostin inhibition diminishes after this window, and bone density gains reverse rapidly without sequential antiresorptive therapy. This makes transition planning a cost consideration from the start.

The ARCH trial used alendronate as the sequential agent, while the FRAME extension study transitioned patients to denosumab [7]. Both sequences maintained or extended the bone mineral density gains achieved during the romosozumab year. Denosumab (Prolia) costs approximately $1,150 every six months in Massachusetts, while generic alendronate costs under $15 per month.

"Sequential therapy after romosozumab is not optional. Stopping without an antiresorptive follow-on results in rapid bone loss that can return fracture risk to baseline within 12-24 months," states the American Association of Clinical Endocrinology 2020 guideline update [8].

Patients and prescribers should factor the total cost of the romosozumab-plus-sequential-therapy sequence when evaluating affordability. A 12-month romosozumab course ($21,900) followed by 3 years of generic alendronate ($540 total) costs substantially less than romosozumab followed by denosumab ($6,900 over 3 years), though the optimal sequential agent depends on individual fracture risk and tolerability.

Strategies to Reduce Out-of-Pocket Cost in Massachusetts

Several approaches can lower the real cost of Evenity for Massachusetts patients. The Amgen copay card handles commercial insurance copays for most eligible patients. Specialty pharmacy shopping rarely yields price differences for biologics, but confirming your plan's preferred specialty pharmacy avoids non-preferred dispensing surcharges of 10-20%.

For Medicare patients, Extra Help (Low-Income Subsidy) reduces Part D cost-sharing to $0-$11.20 per specialty fill for qualifying individuals. Massachusetts also operates the Prescription Advantage program, which supplements Medicare Part D for residents aged 65 and older (or disabled residents of any age) with incomes up to 500% of the federal poverty level.

Patients denied insurance coverage should request a peer-to-peer review between their prescriber and the plan's medical director before filing a formal appeal. Peer-to-peer conversations overturn roughly 40-60% of initial denials for specialty osteoporosis drugs when the prescriber presents fracture risk data and guideline support.

Site-of-care optimization matters too. If your plan covers Evenity under both pharmacy and medical benefits, compare your cost-sharing under each. Medical benefit (buy-and-bill at the physician's office) may carry lower coinsurance than specialty pharmacy benefit for some plan designs, or vice versa. Ask your insurer for a benefits investigation that compares both pathways before starting treatment.